A COMPARATIVE-ANALYSIS OF THE SENSITIVITY OF MULTIDRUG RESISTANT (MDR) AND NON-MDR CELLS TO DIFFERENT ANTHRACYCLINE DERIVATIVES

被引：38

作者：

MICHIELI, M

MICHELUTTI, A

DAMIANI, D

PIPAN, C

RASPADORI, D

LAURIA, F

BACCARANI, M

机构：

[1] Sections of Hematology, Anatomy and Microbiology, Institute of Experimental and Clinical Morphology, University of Udine School of Medicine, Bologna

[2] Institute of Hematology L. e A. Seràgnoli University of Bologna School of Medicine, Bologna

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 9卷 / 03期

关键词：

ANTHRACYCLINES; MULTIDRUG RESISTANCE; CHEMOTHERAPY;

D O I：

10.3109/10428199309147379

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Because of the fact that tumor cell sensitivity to cytotoxic agents may play a major role in cancer treatment, and several anthracyclines are widely used for first-line treatment of leukemia, lymphoma and other tumors, and since the overexpression of the mdr-1 gene-coded 170 Kd glycoprotein (P170) decreases cell sensitivity to anthracyclines, we investigated the relationship between P170 overexpression and the cytotoxicity of two classic anthracyclines (Daunorubicin or DNR and Doxorubicin or DX) and two lipophilic anthracycline derivatives (Idarubicin or IDA and Iododoxorubicin or IDX). For these purposes, we used multidrug resistant (MDR) and non-MDR tumor and leukemia cell lines and the MTT-microcultured tetrazolium colorimetric assay. We showed that mdr-I gene overexpression was strongly associated with the development of a high level of resistance to DNR and DX, but not to the derivatives IDA and IDX. These data suggest that more lipophilic anthracycline derivatives may also be active in MDR cell systems.

引用

页码：255 / 264

页数：10

共 69 条

[51]

Tsuruo T., Iida H., Tsukagoslin S., Sakwai Y., Overcoming of vincristine resistance in P388 leukemia through enhanced cytotoxicity by verapamil, Cancer Res., 41, pp. 1967-1972, (1981)

[52]

Yusa K., Tsuruo T., Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites, and transport of verapamil outward across the plasma membrane of K562/ADM cells, Cancer Res., 49, pp. 5002-5006, (1989)

[53]

Twentyman P.R., Fox N.E., White D.J.G., Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line, Brit. J. Cancer, 56, pp. 55-57, (1987)

[54]

Gosland M.P., Lum B.L., Sikie B.I., Reversal by cefoperazone of resistance to etoposide, doxorubicin and vinblastine in multi-drug resistant human sarcoma cells, Cancer Res., 49, pp. 6901-6905, (1989)

[55]

De Gregorio M.W., Ford J.M., Benz C.C., Wiebe V.J., Toremifene: pharmacologic and pharmacokinetics basis of reversing multidrug resistance, J. Clin. Oncol., 7, pp. 1359-1364, (1989)

[56]

Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F., In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833, Cancer Res., 51, pp. 4226-4233, (1991)

[57]

Berman E., Adams M., Duigou-Osterndorf R., Godfrey L., Clarkson B., Andreeff M., Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype, Blood, 77, pp. 818-825, (1991)

[58]

Krishan A., Sridhar K.S., Davila E., Vogel C., Sternheim W., Patterns of anthracycline retention modulation in human tumor cells, Cytometry, 8, pp. 306-314, (1987)

[59]

Holmes J.A., Multidrug resistance in leukaemia, Leuk. and Lymph., 1, pp. 163-168, (1990)

[60]

Michieli M., Giacca M., Fanin R., Damiani D., Geromin A., Baccarani M., mdr-1 gene amplification in acute lymphoblastic leukaemia prior to antileukaemic treatment, Brit. J. Haematol., 78, pp. 290-291, (1991)

← 1 2 3 4 5 6 7 →